Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 14/20 | 0.65 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.64 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.64 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.64 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.64 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.64 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.64 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.64 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.64 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | DRD2 | P14416 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL723576 | 0.88 | HTR6 (0.65) | HTR6HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL29963796 | 0.88 | HTR6 (0.65) | HTR6HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL2134757 | 0.86 | CYP2A6 (0.51) | HTR6HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL2511497 | 0.82 | HDAC3 (0.78) | HTR6HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL12136686 | 0.81 | HTR6 (0.65) | HTR6HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL17913573 | 0.79 | RAPGEF4 (0.64) | HTR6HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL424532 | 0.79 | HTR6 (0.68) | HTR6HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL706426 | 0.79 | HTR6 (0.68) | HTR6HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL20762478 | 0.79 | HTR6 (0.68) | HTR6HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL17597401 | 0.79 | HTR6 (0.68) | HTR6HDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025038863-A1 | INDOLE AND PYRROLOYPYRIDINE DERIVATIVES AS GPR17 MODULATORS | BIOGEN MA INC. (US) | 2025-02-20 | — | — | WO | disclosed |
| CN-112469710-B | Pyridyl and pyrazinyl- (aza) indole sulfonamides | 优时比制药有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-11939319-B2 | Pyridinyl and pyrazinyl-(asa)indolsulfonamides | UCB PHARMA GMBH (DE) | 2024-03-26 | — | — | US | disclosed |
| US-11939319-B2 | Pyridinyl and pyrazinyl-(asa)indolsulfonamides | UCB PHARMA GMBH (DE) | 2024-03-26 | — | — | US | disclosed |
| US-11939319-B2 | Pyridinyl and pyrazinyl-(asa)indolsulfonamides | UCB PHARMA GMBH (DE) | 2024-03-26 | — | — | US | disclosed |
| EP-4074703-B1 | PYRIDINYL-(AZA)INDOLSULFONAMIDES | UCB PHARMA GMBH (DE) | 2023-11-29 | — | — | EP | disclosed |
| EP-4074703-B1 | PYRIDINYL-(AZA)INDOLSULFONAMIDES | UCB PHARMA GMBH (DE) | 2023-11-29 | — | — | EP | disclosed |
| EP-4074703-A1 | PYRIDINYL-(AZA)INDOLSULFONAMIDES | UCB Pharma GmbH (DE) | 2022-10-19 | — | — | EP | disclosed |
| EP-4074703-A1 | PYRIDINYL-(AZA)INDOLSULFONAMIDES | UCB Pharma GmbH (DE) | 2022-10-19 | — | — | EP | disclosed |
| EP-3810591-B1 | PYRIDINYL AND PYRAZINYL-(AZA)INDOLSULFONAMIDES | UCB PHARMA GMBH (DE) | 2022-08-10 | — | — | EP | disclosed |
| US-20150252030-A1 | N-ACYLHYDRAZONE DERIVATIVES FOR SELECTIVE T CELL INHIBITOR AND ANTI-LYMPHOID MALIGNANCY DRUG | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2015-09-10 | — | — | US | disclosed |
| EP-2890677-A1 | N-ACYLHYDRAZONE DERIVATIVES FOR SELECTIVE T CELL INHIBITOR AND ANTI-LYMPHOID MALIGNANCY DRUG | Chong Kun Dang Pharmaceutical Corp. (KR) | 2015-07-08 | — | — | EP | disclosed |
| CN-104755460-A | N-acylhydrazone derivatives for selective T cell inhibitor and anti-lymphoid malignancy drug | CHONG KUN DANG PHARM CORP | 2015-07-01 | — | — | CN | disclosed |
| US-9029357-B2 | Benzazole derivatives as histamine H4 receptor ligands | BIOPROJET (FR) | 2015-05-12 | — | — | US | disclosed |
| US-20150004181-A1 | Benzazole Derivatives as Histamine H4 Receptor Ligands | BIOPROJET SOC CIV (FR) | 2015-01-01 | — | — | US | disclosed |
| US-8802664-B2 | Benzazole derivatives as histamine H4 receptor ligands | BIOPROJECT (FR) | 2014-08-12 | — | — | US | disclosed |
| WO-2014035149-A1 | N-ACYLHYDRAZONE DERIVATIVES FOR SELECTIVE T CELL INHIBITOR AND ANTI-LYMPHOID MALIGNANCY DRUG | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2014-03-06 | — | — | WO | disclosed |
| US-20130231329-A1 | Benzazole Derivatives as Histamine H4 Receptor Ligands | BIOPROJET (FR) | 2013-09-05 | — | — | US | disclosed |
| EP-2621916-A1 | BENZAZOLE DERIVATIVES AS HISTAMINE H4 RECEPTOR LIGANDS | BIOPROJET (FR) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012041860-A1 | BENZAZOLE DERIVATIVES AS HISTAMINE H4 RECEPTOR LIGANDS | BIOPROJET (FR) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150004181-A1 | Benzazole Derivatives as Histamine H4 Receptor Ligands | HRH4, HRH3, HRH2 | HTR6 57/4885HDAC3 235/4885HDAC4 102/4885 |
| US-20150252030-A1 | N-ACYLHYDRAZONE DERIVATIVES FOR SELECTIVE T CELL INHIBITOR AND ANTI-LYMPHOID MALIGNANCY DRUG | MALT1, MCL1, ACIN1 | HTR6 4486/4885HDAC3 42/4885HDAC4 97/4885 |
| US-11939319-B2 | Pyridinyl and pyrazinyl-(asa)indolsulfonamides | GPR17, GPR18, GPR119 | HTR6 66/4885HDAC3 533/4885HDAC4 686/4885 |
| US-20130231329-A1 | Benzazole Derivatives as Histamine H4 Receptor Ligands | HRH4, HRH3, HRH2 | HTR6 102/4885HDAC3 311/4885HDAC4 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.